Targeted intraabdominal chemotherapy for peritoneal carcinomatosis

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 469-482

  Samel, Stephan ^a   Löhr, Matthias ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CELLULOSE; CELLULOSE SULFATE; CYTOCHROME P450; DRUG DERIVATIVE; IFOSFAMIDE; PRODRUG;

AGED; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CARCINOMA; CELL TRANSPLANTATION; CYTOMEGALOVIRUS; DISEASE MODEL; DRUG DELIVERY SYSTEM; FEMALE; GENETICS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PERITONEUM TUMOR; PROMOTER REGION; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; CELL LINE, TUMOR; CELL TRANSPLANTATION; CELLULOSE; CYTOCHROME P-450 ENZYME SYSTEM; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IFOSFAMIDE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PERITONEAL NEOPLASMS; PRODRUGS; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME;

EID: 84892820968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_32     Document Type: Chapter

References (47)

1. Glehen O, Osinsky D, Beaujard AC, Gilly FN (2003) Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 12:729-39, xiii
2. Glehen O, Gilly FN (2003) Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 12:649-671
3. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD (2001) Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 27:65-73
4. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA (2003) Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 10:155-162
5. Sugarbaker PH (2002) New responsibilities in the management of colorectal cancer with peritoneal seeding. Cancer Invest 20:1118-1122
6. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y (2002) Intracellular targeting therapy of cisplatinencapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99:130-137
7. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB (1995) A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36:91-101
8. Syrigos KN, Vile RG, Peters AM, Harrington KJ (2003) Biodistribution and pharmacokinetics of 111In-dTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol 42:147-153
9. Tabaru K, Konno T, Oda T, Nagamitsu A, Ishimaru Y, Kitamura N (2001) Treatment of VX2 carcinoma implanted in the liver with arterial and intraperitoneal administration of oily anticancer agents. Cancer Chemother Pharmacol 47:149-154
10. Okamoto K, Yamaguchi T, Otsuji E, Yamaoka N, Yata Y, Tsuruta H, Kitamura K, Takahashi T (1998) Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate. Cancer Lett 122:231-236
11. Balthasar JP, Fung HL (1996) Inverse targeting of peritoneal tumours: selective alteration of the disposition of methotrexate through the use of antimethotrexate antibodies and antibody fragments. J Pharm Sci 85:1035-1043
12. Löhr M, Hoffmeyer A, Kröger J, Freund M, Hain J, Holle A, Karle P, Knofel WT, Liebe S, Müller P, Nizze H, Renner M, Saller RM, Wagner T, Hauenstein K, Günzburg WH, Salmons B (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357:1591-1592
13. Löhr M, Kröger JC, Hoffmeyer A, Freund M, Hain J, Holle A, Knöfel WT, Liebe S, Nizze H, Renner M, Saller R, Müller P, Wagner T, Hauenstein K, Salmons B, Günzburg WH (2003) Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther 1:121-131
14. Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R, Nizze H, Nebe B, Liebe S, Salmons B, Günzburg WH (1998) Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther 1998;5:1070-1078
15. Kröger JC, Bergmeister H, Hoffmeyer A, Ceijna M, Karle P, Saller R, Schwendenwein I, von Rombs K, Liebe S, Günzburg WH, Salmons B, Hauenstein K, Losert U, Löhr M (1999) Intraarterial instillation of microencapsulated cells in the pancreatic arteries in pig. Ann N Y Acad Sci 880:374-378
16. Löhr M, Bago ZT, Bergmeister H, Ceijna M, Freund M, Gelbmann W, Günzburg WH, Jesnowski R, Hain J, Hauenstein K, Henninger W, Hoffmeyer A, Karle P, Kröger JC, Kundt G, Liebe S, Losert U, Muller P, Probst A, Puschel K, Renner M, Renz R, Saller R, Salmons B, Walter I, et al (1999) Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intraarterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J Mol Med 77:393-398
17. Dirven HA, van Ommen B, van Bladeren PJ (1996) Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 9:351-360
18. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42
19. Yu LJ, Drewes P, Gustafsson K, Brain EG, Hecht JE, Waxman DJ (1999) In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumour activity. J Pharmacol Exp Ther 288:928-937
20. Struck RF, Dykes DJ, Corbett TH, Suling WJ, Trader MW (1983) Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Br J Cancer 47:15-26
21. Silbermann MH, vd Vecht B, Stoter G, Nooter K, Verweij J (1990) Combination therapy of ACNU and ifosfamide in tumour bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer. Eur J Cancer 26:321-325
22. Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C (1999) Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med Oncol 16:267-278
23. Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN (1998) A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumours. Cancer 82:561-566
24. Chen L, Waxman DJ (1995) Intratumoural activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55:581-589
25. Okada N, Miyamoto H, Yoshioka T, Sakamoto K, Katsume A, Saito H, Nakagawa S, Ohsugi Y, Mayumi T (1997) Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly(L)lysine-alginate (APA) membrane following allogeneic transplantation. Biochem Biophys Res Commun 230:524-527
26. Karle P, Müller P, Renz R, Jesnowski R, Saller R, von Rombs K, Nizze H, Liebe S, Günzburg WH, Salmons B, Löhr M (1998) Intratumoural injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 451:97-106
27. Kammertoens T, Gelbmann W, Karle P, Alton K, Saller R, Salmons B, Günzburg WH, Uckert W (2000) Combined chemotherapy of murine mammary tumours by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther 7:629-636
28. Samel S, Keese M, Lux A, Jesnowski R, Prosst R, Saller R, Hafner M, Sturm J, Post S, Löhr M (2006) Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther 13:65-73
29. Sturm JW, Magdeburg R, Berger K, Petruch B, Samel S, Bonninghoff R, Keese M, Hafner M, Post S (2003) Influence of TNF alpha on the formation of liver metastases in a syngenic mouse model. Int J Cancer 107:11-21
30. Sturm JW, Keese MA, Petruch B, Bonninghoff RG, Zhang H, Gretz N, Hafner M, Post S, McCuskey RS (2003) Enhanced green fluorescent proteintransfection of murine colon carcinoma cells: key for early tumour detection and quantification. Clin Exp Metastasis 20:395-405
31. Löhr JM, Saller R, Salmons B, Günzburg WH (2002) Microencapsulation of genetically engineered cells for cancer therapy. Methods Enzymol 346:603-618
32. Donato MT, Gomez-Lechon MJ, Castell JV (1993) A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 213:29-33
33. Beyer WH (1987) CRC Standard Mathematical Table. 28th ed: Boca Raton, FL: CRC Press
34. Bonenkamp JJ, Sasako M, Hermans J, van de Velde CJ (2001) Tumour load and surgical palliation in gastric cancer. Hepatogastroenterology 48:1219-1221
35. Elias DM, Pocard M (2003) Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 12:543-559
36. Mohamed F, Sugarbaker PH (2002) Peritoneal mesothelioma. Curr Treat Options Oncol 3:375-386
37. Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12:585-603
38. Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277-283
39. Schwartz PS, Waxman DJ (2001) Cyclophosphamide induces caspase 9- dependent apoptosis in 9L tumour cells. Mol Pharmacol 60:1268-1279
40. Karle P, Renner M, Salmons B, Günzburg WH (2001) Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther 8:220-230
41. Zheng JJ, Chan KK, Muggia F (1994) Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemother Pharmacol 33:391-398
42. Jounaidi Y, Hecht JE, Waxman DJ (1998) Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 58:4391-401
43. Chen L, Yu LJ, Waxman DJ (1997) Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 57:4830-4837
44. Jounaidi Y, Waxman DJ (2004) Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 64:292-303
45. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y (2006) Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 5:1021-1028
46. Palmer RR, Lewis AL, Kirkwood LC, Rose SF, Lloyd AW, Vick TA, Stratford PW (2004) Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials 25:4785-4796
47. Löhr M (2006) Gentherapeutische Ansätze bei gastrointestinalen Tumouren (Gene Therapy of Gastrointestinal Tumours). Z Gastroenterol 44:1-8